Kymera Therapeutics, Inc.KYMRNASDAQ
Loading
R&D Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+24.5%
5Y CAGR+38.5%
Year-over-Year Change
Research and development spending
3Y CAGR
+24.5%/yr
vs +74.6%/yr prior
5Y CAGR
+38.5%/yr
Recent deceleration
Acceleration
-50.1pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
5.1x
Strong expansion
Streak
7 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $316.60M | +31.8% |
| 2024 | $240.25M | +27.1% |
| 2023 | $189.08M | +15.1% |
| 2022 | $164.25M | +19.9% |
| 2021 | $137.02M | +120.6% |
| 2020 | $62.10M | +67.1% |
| 2019 | $37.16M | +110.2% |
| 2018 | $17.68M | - |